Inhibition of pulmonary metastases poses a difficult clinical challenge for current therapeutic regimens. We have developed an aerosol system utilizing a cationic polymer, polyethyleneimine ( PEI ), for topical gene delivery to the lungs as a novel approach for treatment of lung cancer. Using a B16 -F10 murine melanoma model in C57BL / 6 mice, we previously demonstrated that aerosol delivery of PEI -p53 DNA resulted in highly significant reductions in the tumor burden ( P < .001 ) in treated animals, and also lead to about 50% increase in the mean length of survival of the mice -bearing B16 -F10 lung tumors. The mechanisms of this antitumor effect of p53 are investigated in this report. Here, we demonstrate that the p53 transfection leads to an up -regulation of the antiangiogenic factor thrombospondin -1 ( TSP -1 ) in the lung tissue and the serum of the mice. Furthermore, there is a downregulation of vascular endothelial growth factor ( VEGF ) in the lung tissue and serum of the B16 -F10 tumor -bearing mice treated with PEI -p53 DNA complexes, compared with untreated tumor -bearing animals. In addition, staining for von Willebrand factor ( vWF ), a marker for the angiogenic blood vessels, revealed that p53 treatment leads to a decrease in the angiogenic phenotype of the B16 -F10 tumors. Immunohistochemistry for transgene expression reveals that the PEI -p53 aerosol complexes transfect mainly the epithelial cells lining the airways, with diffuse transfection in the alveolar lining cells, as well as, the tumor foci in the lung tissue. There was also some evidence of apoptosis in the lung tumor foci of animals treated with p53. The data suggest that aerosol delivery of PEI -p53 complexes leads to inhibition of B16 -F10 lung metastases, in part by suppression of angiogenesis.
L ung cancer is the single largest cause of cancer deaths, with approximately 175,000 deaths reported every year in US alone. More than 80% of lung cancers do not respond favorably to irradiation or chemotherapy. p53 tumor suppressor gene mutations are reported in a majority of lung cancers resulting in decreased apoptosis, and increased drug resistance and tumor relapse. 1, 2 A novel approach in cancer treatment is p53 gene replacement therapy to reverse the molecular dysfunctions and suppress the tumor growth. 3 Apart from its role in tumor suppression through the classical apoptotic pathways, p53 has also been demonstrated to regulate angiogenesis. 4 -6 Angiogenesis plays a central role in many different physiological processes such as reproduction, tissue repair and development. However, in some diseases such as cancer, the neovascularization process is abnormal with accelerated growth of new blood vessels into the tumor, enhancing the tumor growth and metastases. 7 This tumor property presents another potential target for cancer therapy. If the blood supply to the tumor mass is eliminated or restricted, it is possible to reduce or even eliminate the tumor mass. Angiogenesis is controlled by a delicate balance between angiogenic stimulators and inhibitors. Many tumor cells seem to up-regulate one or the other angiogenic stimulators, such as vascular endothelial growth factor ( VEGF ) or fibroblast growth factor ( FGF ). 8 Concurrently, certain endogenous angiogenic inhibitors such as thrombospondin ( TSP -1) are down -regulated, 9 resulting in the transformation of the tumor from a quiescent to an angiogenic phenotype. Angiogenesis has been demonstrated to play an important role in tumor metastases to the lungs 10 and modulation of this process can serve as a basis for lung cancer therapies.
Different approaches that target the p53 gene to the lungs, such as instillation and intravenous delivery, have been reported to have a therapeutic effect in pulmonary cancer models. 11, 12 However, these strategies are invasive or they may not distribute the material uniformly throughout the pulmonary tissue. Currently, techniques used for administering gene delivery vectors to the lungs employ injections through computed tomography -guided percutaneous fineneedle injections or bronchoscopy. 13 These procedures are very invasive and target restricted regions of the lungs. In contrast, aerosol delivery distributes the complexes uniformly and represents a noninvasive alternative for topical delivery of therapeutic genes to the lungs.
Recently, we demonstrated that polyethyleneimine ( PEI ), a cationic polymer, holds promise as a gene delivery vector by aerosol, 14, 15 and provided evidence that the delivery can lead to an anticancer response in two different lung cancer models using the p53 tumor suppressor gene. 16, 17 Also, PEI -DNA aerosol delivery is not associated with acute inflammatory or cytokine responses, in contrast to that reported for cationic liposomes and viral vectors. 15, 18 In this report, we demonstrate that after aerosol delivery, p53 induces antiangiogenic mechanisms to suppress the development of B16 -F10 melanoma lung metastases.
Materials and methods

Animals
Female C57BL /6 mice (7 -8 weeks old; Harlan SpragueDawley, Houston, TX ) were used for the B16 -F10 melanoma studies.
Plasmid DNA
The p53 gene under the control of the human cytomegalovirus (CMV ) promoter /enhancer element was a gift of Dr. YK Fung (Childrens Hospital, Los Angeles, CA ). The plasmid used for localization studies (p4119) contains the bacterial chloramphenicol acetyl transferase (CAT ) gene under the control of the CMV promoter / enhancer element. The luciferase plasmid (Luc ) under the control of the CMV promoter /enhancer element was a gift from Dr. Michael Barry (Center for Cell and Gene Therapy, Baylor, TX ). The plasmids were purified commercially by Bayou Biolabs (Harahan, LA ), were predominantly supercoiled, endotoxin free, and were quantitated using UV absorbance.
Preparation of PEI -DNA complexes
A PEI ( 25-kDa branched; Aldrich, Milwaukee, IL ) stock solution was prepared at a concentration of 4.3 mg / mL ( 0.1 M in nitrogen ) in H 2 O, and the pH was adjusted to 7 -7.5 with 1 M HCl. Ten milliliters of PEI -DNA complexes at the required concentration of 2 mg / 10 mL was prepared as previously described. 15 The complexes were allowed to stand at room temperature for about 15 -20 minutes before nebulization. The resulting charge ratio is expressed as PEI nitrogen:DNA phosphate (N:P), which can be calculated by taking into account that DNA has 3 nmol of phosphate / g and 1 l of 0.1 M PEI solution has 100 nmol of amine nitrogen. A 10:1 N:P ratio corresponds to 1.29:1 PEI:DNA weight ratio.
Delivery of PEI -DNA complexes
Mice were placed in plastic cages that were sealed with tape before aerosol delivery. This is an unrestrained, whole -body aerosol exposure system. PEI -DNA complexes were aerosolized using an Aerotech II nebulizer (AT-II ) ( CIS -US, Bedford, MA ) at 10 L /min flow rate using air containing 5% CO 2 for enhanced deposition in the lungs by increasing minute volume. 15 The aerosol delivery of 10 mL solution takes about 30 minutes.
B16 -F10 melanoma cell line
B16 -F10 was obtained from Division of Cancer Treatment and Diagnosis Center (DCTDC, NCI, Frederick, MD ) and cultivated in DMEM supplemented with 10% fetal calf serum. The cell line has been shown to form tumors in the lung and the model has been previously described. 19 Twenty five thousand B16 -F10 cells in 200 l of media were injected per mice via the tail vein of C57BL / 6 mice. Lung metastases are visually detected within 10 days after inoculation of cells. The cells were used at passages 3-12.
Immunohistochemistry
Lungs were isolated, cannulated via the trachea and fixed by inflation with 50% (vol /vol ) OCT ( optimal cutting compound, Sakura Finetek, Torrance, CA ) in saline. Cryosections were cut at 5 m, collected on slides, air dried, and incubated with 0.6% H 2 O 2 for 20 minutes to inactivate endogenous peroxidase activity.
CAT immunohistochemistry. The slides were blocked using 5% FBS for 30 minutes at room temperature. The slides were then incubated with a sheep polyclonal antibody to CAT ( digoxigenin labeled antibody, 20 g /mL; Roche Diagnostics, Indianapolis, IN ) for 1 hour at RT. After washing with PBS, the sections were incubated with an antibody to digoxigenin labeled with peroxidase (1:150 dilution, Roche Diagnostics ) for 1 hour at RT. The slides were then developed using aminoethylcarbazol ( AEC ) for 3 -5 minutes. Lungs from naïve mice were used as controls. Sections in which the primary antibody was excluded were also used as controls.
von Willebrand factor ( vWF ) staining. Lungs from naïve and tumor-bearing mice were inflated with neutral buffered formalin ( NBF ) and processed and embedded in paraffin. Thin sections ( 5 m ) were collected on slides and deparaffinized. After inactivation of endogenous H 2 O 2 , the slides were incubated with 20% normal goat serum for 30 minutes at room temperature. The slides were then incubated with rabbit anti -vWF ( 1:300; Dako, Glostrup, Denmark ). After washing with PBS, the slides were incubated with biotin -labeled goat anti -rabbit IgG ( 1:1000; Dako ). The slides were then incubated with avidin-peroxidase conjugate (1:200; Vector Laboratories, Burlingame, CA ) for 30 minutes at RT and developed with AEC for 3-5 minutes. Lungs from naïve mice were used as controls. Sections in which the primary antibody was excluded were also used as controls.
In situ cell death detection ( apoptosis )
Lungs from tumor-bearing mice, both untreated and p53-treated, were analyzed for apoptosis using the apoptosis detection system ( Promega, Madison, WI ). Mice were anaesthetized with isoflurane and sacrificed by exsanguination via the abdominal aorta. Lungs were isolated, cannulated, and fixed by inflation with 10% NBF, embedded in paraffin, and processed for histological analysis. Thin sections were cut at 5 m, and processed for apoptosis staining. Briefly, slides were incubated with proteinase K (20 mg / mL in 10 mM Tris -HCl buffer, pH 7.4 -8.0) for 30 minutes at room temperature. The slides were then incubated with 3% H 2 O 2 in methanol for 20 minutes to inactivate endogenous peroxidase activity. The sections were permeabilized with 0.1% Triton X -100 in 0.1% sodium citrate for 2 minutes on ice, rinsed with PBS and then incubated for 60 minutes at 378C with the TUNEL reaction mixture available with the kit. The slides were then washed with PBS and visualized under the fluorescence microscope fitted with an epifluorescence condenser IV F1 (Zeiss, Oberkochen, Germany ). Green fluorescence was observed using a filter (excitation wavelength 450-490 nm ). Images were obtained using an MC 80 microscope camera.
VEGF and TSP -1 ELISA
VEGF and TSP -1 levels in the serum and the lung tissue of the mice were evaluated using ELISA. The mice were bled from the abdominal aorta and the blood was collected. The blood was incubated at room temperature for 2 hours and then centrifuged at 14,000Âg for 10 minutes. Serum was collected and frozen at À 808C until further assay. The lungs were harvested after perfusion with PBS through the heart, and homogenized with a Wig -L -Bug ( Crescent Dental, Lyons, IL ) bead homogenizer using 1 mL of ice -cold extraction buffer ( 50 mM Tris, pH 8, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X -100, 1 M pepstatin A, 0.25 mM PMSF and 10 M leupeptin ). The homogenate was centrifuged and the supernatant frozen at À 808C until further use. Samples from naïve mice were used as controls. All procedures on mice were performed under anesthesia. The ELISA kit for VEGF was purchased from R&D Systems ( Minneapolis, MN ). The TSP -1 ELISA was developed as previously described, 20 using goat anti -TSP1 (7.5 g /mL; Santa Cruz Biotechnology, Santa Cruz, CA ) and rabbit anti -TSP1 antibodies (1:1000 dilution; Biodesign, Saco, ME ). The sensitivity of both the assays is 10 pg /mL.
Results
Transfection of tumor foci with PEI -DNA complexes
We have previously demonstrated that aerosol delivery of PEI -p53 DNA complexes results in a highly significant antitumor effect in the B16 -F10 melanoma lung metastases model. 16 To study this antitumor mechanism of p53, we initially visualized the transgene expression in the pulmonary cells after PEI -DNA aerosol delivery. Mice were injected with 25,000 B16 -F10 cells i.v. on day 0, and the tumor was allowed to establish until day 10. On day 11, when tumor foci are visible, the mice were aerosolized with PEI -CAT DNA complexes. Twenty -four hours after aerosol delivery, mice were sacrificed, the lungs were processed and the CAT expression was detected by immunohistochemistry. As shown in Figure 1 , the complexes not only transfect the airway epithelial cells, but also the tumor foci in the lung tissue (shown by arrows in the figure ). The expression of p53 in the lungs of mice, both by ELISA and immunohistochemistry, following PEI -p53 DNA aerosol delivery has been previously reported with similar distribution. 16, 17 Also, CAT expression in the lungs of naïve animals has been visualized using immunohistochemistry previously, and we detected a similar pattern of transfection after PEI -CAT DNA aerosol delivery. 21 vWF staining in B16 -F10 tumor -bearing lungs Angiogenesis has been demonstrated to be essential for tumor growth and metastases. Because the gene expression was mainly localized in the airway epithelial cells, and to a certain extent in the tumor foci (Fig 1) , we hypothesized that the p53 antitumor effect could be through an antiangiogenic mechanism. To investigate the angiogenic phenotype of the B16 -F10 cells in vivo, mice were injected with 25,000 B16 -F10 tumor cells on day 0. At different time points (days 4, 7, 10, 14, 18, and 21), mice were sacrificed and the lungs were processed for vWF staining, a marker for angiogenesis 22 as described in Materials and methods. The intensity of vWF staining increased with the time, suggesting the role of angiogenesis in the metastases and progression of the tumor in the lungs (day 14 and 18 time points are shown in Fig 2) . An interesting observation was that the smaller tumor foci had intense staining for the newly formed vessels (Fig 2D ) , and as the tumor cells grew larger they encompassed the blood vessels and grew around it (Fig 2C ) , further suggesting a role for angiogenesis in initial growth of tumor metastases. Furthermore, p53 treatment of animals injected with B16 -F10 cells led to a decrease in the vWF staining ( Fig 2E and F) , suggesting that p53 leads to inhibition of metastases through regulation of angiogenesis. The number and size of tumor foci, as well as vWF staining is reduced for p53 -treated animals (Fig 2   Figure 1 Transfection of tumor foci by PEI -DNA aerosol complexes. A total of 25,000 B16 -F10 cells were injected into the mice and on day 11 post tumor inoculation, 2 mg of CAT plasmid was complexed with PEI at an N:P ratio of 10:1 and the complexes were aerosolized to the mice using 5% CO 2 in air. Twentyfour hours after aerosol delivery, mice were sacrificed and lungs processed for CAT immunohistochemistry. A: The CAT staining in the black tumor foci is shown by the arrow. B: Lung section from an untreated tumor -bearing mouse processed for CAT staining.
and Ref. [16 ] ). Furthermore, we quantitated the microvessel density at 20Â magnification in both the untreated and p53 -treated tumor-bearing animals, and p53-treated animals showed a significant degree of reduction in number of stained vessels (15.7 ± 3.4 microvessels /field for untreated on day 14, and 2.3 ± 0.6 microvessels /field for p53; P < .01, Student's t test; three animals per group, three sections per animal, six fields per section ). Moreover, B16 -F10 cell supernatant also induced increased endothelial cell proliferation in an in vitro angiogenesis assay, and this was reversed by p53 transfection of the tumor cells ( data not shown). p53 transfection decreases VEGF levels in the lungs and serum of tumor -bearing mice VEGF is known to regulate the expression of vWF. 22 To determine if the increased vWF staining correlates with increased VEGF levels, serum and lung tissue levels of VEGF were assayed by ELISA. Mice were injected with 25,000 B16 -F10 cells on day 0. Mice were treated with PEI -p53 DNA or PEI -Luc DNA aerosol complexes on days 4, 7, 11, 14, 17, and 20 post tumor injection, or left untreated. Twenty-four hours after exposure at each time point ( on days 5, 8,12,15, 18, and 21 post tumor cell inoculation for p53, and on days 12 and 15 for Luc ), the mice were sacrificed and the VEGF levels in the lungs and serum were assayed by ELISA. The levels of VEGF increased with time after tumor cell inoculation, and were 2-to 3 -fold higher in the tumor-bearing mice compared with naïve tumor-free animals (P < .01, Student's t test ). Furthermore, aerosol delivery of PEI -p53 DNA complexes to the tumorbearing mice resulted in reduced VEGF levels in these animals (Fig 3, P < .01 ) . The level of VEGF in the PEILuc -treated animals was similar to untreated tumor-bearing animals ( serum values for day 12, 271.38± 38.78 for control and 256 ± 35.26 for Luc; P >.1, Student's t test ). Aerosol exposure of PEI -p53 DNA complexes to naïve animals did not result in any change in the VEGF levels, compared with naïve unexposed animals. The results were similar to that obtained when B16 -F10 cells were transfected in vitro with PEI -p53 complexes, although the decrease in VEGF levels was greater because of increased transfection efficiency ( data not shown ). , and days 12 and 15 for Luc ), the mice were sacrificed and the VEGF levels in the lungs and serum were assayed by ELISA. Values are mean ± SD ( n = 3 mice per group, P < .01 p53 vs. control ). The samples were diluted 1:5, and the lung levels were standardized to the lung weight. Data is representative of at least two separate experiments. A: Lung. B: Serum. Levels of VEGF in non -tumorbearing animals were similar to p53 -treated animals. Control: tumorbearing animals; p53: tumor -bearing animals treated with PEI -p53 DNA aerosol complexes. 
Cancer Gene Therapy p53 transfection results in TSP -1 up -regulation
Because p53 is known to positively regulate the antiangiogenic factor thrombospondin -1 (TSP -1 ) in other systems, 4 we wanted to test if p53 transfection in the lung tissue would also result in an up -regulation of TSP -1. Mice were injected with 25,000 B16 -F10 cells on day 0. Mice were treated with PEI -p53 DNA or PEI -Luc DNA aerosol complexes on days 4, 7, 11, 14, 17, and 20 post tumor injection, or left untreated. Twenty-four hours after exposure at each time point (on days 5, 8, 12, 15, 18 , and 21 post tumor cell inoculation for p53, and days 12 and 15 for Luc ), the mice were sacrificed and the TSP -1 levels in the lungs and serum were assayed by ELISA. Naïve mice were also exposed to either PEI -Luc or PEI -p53 DNA aerosol complexes. There was a 2-to 3-fold increase in the levels of TSP -1 both in the lung tissue and the serum of the p53 -treated mice (Fig 4, P < .01, Student's t test ) . The level of TSP -1 in the PEI -Luc -treated animals was similar to untreated controls (serum values for day 12, 132.89± 17.56 for control and 140.67 ± 18.37 for Luc; P >.1, Students t test ).
The TSP -1 baseline levels at day 5 for p53 -treated animals was higher than for untreated tumor-bearing animals, suggesting that the epithelial cells might be a likely source of TSP -1 up -regulation and secretion after p53 transfection. Also, the level of TSP -1 after PEI -p53 DNA aerosol delivery was higher in tumor-bearing mice compared with naïve mice suggesting that the transfection of the tumor cells by p53 results in a further up-regulation of TSP -1. We are currently investigating the expression of TSP -1 in the lung tissue after p53 transfection at the cellular level by immunohistochemistry.
Induction of apoptosis in lung tumor foci
Because the PEI -DNA complexes transfect the B16 -F10 tumor foci in the lungs (Fig 1 ) , we wanted to study the direct apoptotic effect of p53 transfection on the B16 -F10 lung foci. Mice were injected with 25,000 B16 -F10 cells on day 0, and the mice were treated with PEI -p53 DNA complexes on day 11. On day 12, the mice were sacrificed and the lungs processed for in situ apoptosis detection as explained in Figure 5 p53 induces apoptosis in tumor foci. Mice were injected with 25,000 B16 -F10 cells on day 0, and the mice were treated with PEI -p53 DNA complexes on day 11 ( 2 mg / 10 mL p53 DNA complexed with PEI at an N:P ratio of 10:1 ). On day 12, the mice were sacrificed and the lungs processed for in situ apoptosis detection. A: Control -bright light. B: Control -fluorescent light. C: p53 -bright light. D: p53 -fluorescent light. Sections are representative of three animals ( three sections per animal, three fields per section ).
Materials and methods. The cells on the periphery of the tumor foci were positive for apoptosis in the p53 -treated animals, compared with the untreated tumor-bearing animals ( Fig 5 ) . However, there was not much evidence of apoptotic cells within the tumor foci. Also, because the center of the tumor focus is necrotic, there might not be much evidence of apoptosis after p53 transfection, compared with the peripheral cells, which are actively dividing and undergo apoptosis on p53 transfection and expression.
Discussion
Gene therapy holds promise for a variety of human diseases, particularly those that have proven to be refractory to traditional forms of therapies. Cancer gene therapy is one of the most intensely investigated fields of research, with lung cancer being of major interest. Various vector systems and routes of administration have been investigated for gene delivery to the lungs, with varying degree of success. Effective inhibition and treatment of tumor metastases to the lungs remains a major concern for most clinical settings.
Angiogenesis, or new blood vessel formation, has been shown to be a key regulator for tumor metastasis, as well as for growth of microfoci into macrometastases. 7 The transition of tumor cells from a dormant into an angiogenic phenotype is triggered by what is termed as the ''angiogenic switch''. 7 Through mutating key regulatory genes, the tumor cells upregulate angiogenic factors with a concomitant downregulation of the antiangiogenic factors. This imbalance between the angiogenic and the antiangiogenic factors helps the tumor cells to induce fresh blood vessel formation facilitating it to metastasize and invade other tissues.
Our data presented here demonstrate that aerosol delivery of PEI -p53 DNA complexes inhibits lung metastases through suppression of angiogenesis. Aerosol delivery of PEI -p53 DNA complexes to the mice leads to a significant increase in the lung tissue and serum levels of the antiangiogenic factor TSP -1, both for naïve and tumorbearing animals. Volpert et al 23 have previously reported that TSP -1 can inhibit the lung metastasis of B16 -F10 melanoma. However, they used purified TSP -1 injections in their experimental protocols. Further, they showed that a subcutaneous tumor producing large amounts of TSP -1 could also inhibit B16 -F10 lung metastasis. In our system, TSP -1 up -regulation and secretion, with the airway epithelial cells as one likely source based on immunohistochemistry, after transfection by p53 leads to suppression of the B16 -F10 lung metastases. TSP -1 has also been demonstrated to induce apoptosis in activated endothelial cells in angiogenic blood vessels. 24 Because TSP -1 has a half -life of about 8-10 hours in the mouse serum, even a modest up -regulation in the levels of TSP -1 can have a prolonged effect on the metastases of tumor cells. The fact that there is no evidence of any extrapulmonary B16 -F10 metastases in the p53 -treated mice 16 can be explained, in part, by the observation reported here that the serum levels of TSP -1 are elevated, which could prevent these metastases, as well as their growth. Thrombospondin gene therapy has been demonstrated to result in an anticancer effect in different tumor models. 25, 26 We are currently investigating the effect of aerosol delivery of PEI -TSP DNA complexes on B16 -F10 lung metastases.
Transfection of the lung tumor foci by PEI -p53 complexes also lead to down -regulation of the angiogenic factor VEGF in the lung tissue and the serum of the mice. P53 has been shown to bind to the promoter sequence of VEGF and negatively regulate the levels and secretion of VEGF. 27 Levels of VEGF secretion from tumor cells correlate with the angiogenic phenotype of the tumor, and VEGF plays a key role in the control of angiogenesis due to its ability to enhance vascular permeability as well as mitogenic stimulation of vascular endothelial cells. In the B16 -F10 tumor-bearing lungs, the increased staining for the vWF correlates with the elevated VEGF levels in the lung tissue. Furthermore, down -regulation of VEGF secretion by the B16 -F10 cells after transfection by p53 inhibits the angiogenic phenotype of the B16 -F10 cells, thereby inhibiting growth of micrometastases into macrometastases. Our data are consistent with other studies showing that regulation of VEGF by p53 modulates the tumor growth and metastasis. 28, 29 Furthermore, B16 -F10 melanoma has been shown to induce angiogenesis in vivo and various antiangiogenic agents have been tested to inhibit tumor growth. 30, 31 Our study is the first to demonstrate that aerosol delivery of the p53 gene can also induce an antiangiogenic mechanism and inhibit B16 -F10 tumor growth.
In situ staining for apoptosis revealed that p53 induces programmed cell death in some of the peripheral cells of tumor foci. However, there was no significant number of apoptotic cells within the tumor foci. It is possible that PEIp53 DNA aerosol complexes can transfect only the peripheral cells that are easily accessible, and cannot diffuse to the cells with the tumor foci. The proapoptotic factors possibly up -regulated by p53 transfection of B16 -F10 cells are not known, although there are a number of possibilities. Kalechman et al, 32 have previously shown that AS101 ( ammonium trichloror( dioxoethylene -0,0 0 )tellurate ), a synthetic immunomodulator can up -regulate p53 expression in B16 -F10 cells and they postulated that the increased p53 levels induced apoptosis in B16 -F10 cells via the upregulation of Fas /Apo -1. Other factors such as Bax and Bcl -2 could also be regulated by p53 transfection, and the mechanism is currently under investigation in our laboratory. Inhibition of angiogenesis, which can also induce apoptosis in tumor cells, could also be involved in the apoptosis mechanism. 6 The model for the p53 antitumor effect that we propose from our studies is depicted in Figure 6 . After tumor inoculation into the mice on day 0, the treatment is started on day 1. Because there are no tumor foci on day 1, the PEIp53 DNA aerosol complexes mainly transfect the airway epithelial cells, with some diffuse transfection of alveolar cells, leading to an up-regulation and secretion of TSP -1 into the lung tissue and the serum. TSP -1 acts as an angiogenic inhibitor and prevents the development of B16 -F10 melanoma lung metastasis. Around day 10, when some of the tumor cells do form microfoci in the lung tissue, transfection of these foci by PEI -p53 DNA aerosol complexes leads to further up -regulation and secretion of TSP -1. Furthermore, the transfection of these tumor foci by p53 also down -regulates the secretion of the angiogenic factor VEGF. The combined effect results in the suppression of angiogenesis, thereby inhibiting metastases as well as inhibiting the growth of micrometastases into macrometastases. The other potential arm of the antitumor pathway shown in the model, namely the induction of apoptosis by p53, is being further investigated in our laboratory and could play a crucial role in tumor suppression, although the data suggest that the major pathway in this system is likely the antiangiogenic mechanism of p53.
We have previously demonstrated in a human osteosarcoma lung metastases model, where the tumor foci were allowed to establish before initiating the treatment, that aerosol delivery of PEI -p53 DNA complexes has a very significant antitumor effect. 17 Although the tumor foci were not eliminated in the p53 -treated mice, they were significantly smaller than those evident in the control animals. The LM -6 osteosarcoma model, which represents a model for growth inhibition of established lung metastases, is very different from the B16 -F10 melanoma model, where the treatment is initiated a day after tumor cell inoculation and represents a model for inhibition of lung metastasis. 16 The B16 -F10 model is developed in C57BL /6 mice, which are immune competent compared with the LM -6 osteosarcoma model that grows in the immune compromised athymic nude mice. The exact mechanism of p53 action in the LM -6 osteosarcoma model is currently under investigation in our laboratory. However, it is possible that regulation of angiogenesis by p53 also plays an important role in the growth suppression of established osteosarcoma lung metastases.
In this study, we have demonstrated that aerosol delivery of PEI -p53 DNA complexes can inhibit lung metastasis, in part, through the suppression of angiogenesis, by upregulating TSP -1 and down -regulation of VEGF. Aerosol delivery of PEI -p53 DNA complexes represents an attractive alternative strategy for delivery of therapeutic genes to the pulmonary tissue for diseases such as lung cancer, and the data presented here argue for consideration of this strategy in clinical trials for lung cancer. 
